Physician profile
Barton B Thrasher
NPI 1740223460
$5,746.16
in general payments reported to CMS, 2019-2025
36 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $1,758 · 2021: $840 · 2022: $904 · 2023: $323 · 2024: $211 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $888.01 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $729.20 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $675.96 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $434.86 | 2019-2023 | |
| Glaxosmithkline, LLC. | $358.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.08 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $304.29 | 2021-2025 | |
| Abbvie INC. | $261.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $199.27 | 2019-2025 | Spravato |
| Abbott Laboratories | $174.09 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $160.51 | 2019-2021 | |
| Allergan, INC. | $139.44 | 2019-2020 | |
| Astellas Pharma US INC | $123.26 | 2019-2023 | Veozah |
| Pacira Therapeutics, INC. | $95.67 | 2019-2020 | |
| Antares Pharma, INC. | $85.61 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $83.82 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $81.08 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $72.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $62.09 | 2020-2025 | Zoryve |
| Nalpropion Pharmaceuticals LLC | $60.80 | 2019 | |
| Amgen INC. | $60.78 | 2020 | |
| C2n Diagnostics, LLC | $56.49 | 2025 | Precivityad2 |
| Takeda Pharmaceuticals U.S.A., INC. | $50.60 | 2019-2021 | |
| Genentech USA, INC. | $40.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $30.05 | 2021 | |
| Shire North American Group INC | $28.78 | 2019 | |
| Exact Sciences Corporation | $28.30 | 2023-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $22.53 | 2025 | Flucelvax, Fluad |
| Halozyme INC | $20.57 | 2023 | |
| Edwards Lifesciences Corporation | $18.45 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $15.05 | 2021 | |
| Inspire Medical Systems, INC. | $14.84 | 2025 | Inspire |
| Mission Pharmacal Company | $14.57 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.13 | 2024 | Voquezna |
| Lundbeck LLC | $13.63 | 2024 | Rexulti |
| Mylan Specialty L.P. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barton Thrasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.